These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 815998)

  • 21. Sensitivity of thrombin and plasmin to heparin and antithrombin III.
    Bauer PI; Breuer Z; Machovich R; Büki KG; Horváth I
    Acta Biochim Biophys Acad Sci Hung; 1985; 20(3-4):155-61. PubMed ID: 2944348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new assay for the measurement of total progressive antithrombin.
    Lane JL; Bird P; Rizza CR
    Br J Haematol; 1975 May; 30(1):103-15. PubMed ID: 53064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The assay of antithrombin using a synthetic chromogenic substrate for thrombin.
    Blombäck M; Blombäck B; Olsson P; Svendsen L
    Thromb Res; 1974 Nov; 5(5):621-32. PubMed ID: 4445986
    [No Abstract]   [Full Text] [Related]  

  • 25. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
    Tran TH; Duckert F
    Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous antithrombin in a patient with benign paraprotein.
    Gabriel DA; Carr ME; Cook L; Roberts HR
    Am J Hematol; 1987 May; 25(1):85-93. PubMed ID: 3578266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rivanol method for the quantitative determination of antithrombin III in plasma.
    Yue RH; Starr T; Gertler MM
    Thromb Diath Haemorrh; 1974 Jun; 31(3):439-51. PubMed ID: 4423843
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthetic peptide substrates in hemostatic testing.
    Fareed J; Messmore HL; Walenga JM; Bermes EW
    Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GAGs-potentiated inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III - correlation with total charge density.
    Cofrancesco E; Vigo A; Pogliani EM
    Thromb Haemost; 1981 Dec; 46(4):749-51. PubMed ID: 6460339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombin activity of intact human platelets.
    Watanabe K; Chao FC; Tullis JL
    Thromb Diath Haemorrh; 1975 Sep; 34(1):115-26. PubMed ID: 52897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory determination of heparin cofactor II.
    Ezenagu LC; Brandt JT
    Arch Pathol Lab Med; 1986 Dec; 110(12):1149-51. PubMed ID: 3778142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usage.
    Fareed J; Walenga JM; Svendsen LG; Bermes EW
    Semin Thromb Hemost; 1986 Oct; 12(4):310-7. PubMed ID: 3787268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effect of heparin in thrombin-antithrombin III interaction.
    Marciniak E
    Thromb Diath Haemorrh; 1975 Dec; 34(3):748-62. PubMed ID: 1209544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].
    Broncel M; Marczyk I; Kostka B; Michalska M; Sikora J; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):21-4. PubMed ID: 17477084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential.
    Hemker HC; Wielders S; Kessels H; Béguin S
    Thromb Haemost; 1993 Oct; 70(4):617-24. PubMed ID: 7509511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombin III and heparin inactivation in thrombin involving reactions.
    Marciniak E
    Thromb Haemost; 1977 Aug; 38(2):486-93. PubMed ID: 579490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Thrombin, antithrombin, thrombin-antithrombin complex (TAT)].
    Sakata T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():626-8. PubMed ID: 15658407
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.